2026-W46 · Nov 9–Nov 15 · Company · Profile · published
West Pharmaceutical company profile · pharma packaging & drug delivery components (vials, stoppers) · history · financial snapshot · S&P 500 rank #336 · 西氏製藥服務公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | WST (NYSE) |
| Company | West Pharmaceutical Services, Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #336 · 0.04% (Nov 2, 2026) |
| Sector rank (by market cap) | #44 in Health Care (Nov 2, 2026) |
| Share price (frozen benchmark) | $408.52 (Nov 2, 2026) |
| Headquarters | Exton, Pennsylvania |
| Founded | 1923 (as The West Company) |
| CEO | Eric M. Green (President and CEO) |
| Employees | about 10,800 (FY2025 year-end) |
| Market cap | $28.46B (Nov 2, 2026) |
WHAT IT DOES
West Pharmaceutical Services makes the packaging and delivery components that injectable drugs travel in — rubber stoppers, seals, glass vials and plungers, plus drug-delivery devices — selling to pharmaceutical and biotech companies worldwide.
The model is consumables plus validation: once a stopper or vial is qualified in a drug's filing, switching suppliers is costly, so volumes follow drug production. FY2025 revenue was $3,074M, up 6.3% from $2,893M, operating income was $636M, net income was $493.7M, and diluted EPS was $6.83.
One provider reports operating income of $617M on a different line basis — the $636M figure is used and the difference is flagged. The company had 25 manufacturing facilities at year-end, 26 after the 2026 Dublin expansion; the 26 figure is NOT a FY2025 figure and is not presented as one.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Proprietary Products | — | — | — |
| Contract-Manufactured Products | — | — | — |
HISTORY
| Year | Milestone |
|---|---|
| 1923 | The West Company founded |
| 2020 | Components in high demand as COVID-19 vaccines scale up |
| 2025 | FY2025 revenue reaches $3,074M, up 6.3%, with 25 manufacturing facilities at year-end |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenue | $3,074M (+6.3% YoY) |
| Operating income | $636M |
| Net income | $493.7M |
| Diluted EPS | $6.83 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
West Pharmaceutical Services is the S&P 500's injectable-packaging name: at a 0.04% index weight and #44 in Health Care by market cap, it is the index's main exposure to drug-delivery components.
Its volumes are a standing read on biologics production — vial and stopper orders move before drug sales do.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | West Pharmaceutical Services FY2025 results / Form 10-K, filed Feb 17, 2026 (fiscal year ended Dec 31, 2025), company profile sources |
| Sector classification | GICS (Life Sciences Tools & Services) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | WST(NYSE) |
| 公司 | West Pharmaceutical Services, Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/生命科學工具與服務 |
| 標普500排名(按權重) | #336 · 0.04%(2026 年 11 月 2 日) |
| 板塊內排名(按市值) | 醫療保健第 #44(2026 年 11 月 2 日) |
| 股價(凍結基準) | $408.52(2026 年 11 月 2 日) |
| 總部 | 美國賓夕法尼亞州埃克斯頓 |
| 成立 | 1923 年(前身為 The West Company) |
| 行政總裁 | Eric M. Green(總裁兼行政總裁) |
| 員工 | 約 10,800(FY2025 年末) |
| 市值 | $28.46B(2026 年 11 月 2 日) |
業務概覽
西氏製藥服務製造注射藥物所用的包裝與輸送零件——橡膠塞、密封件、玻璃瓶與推桿,以及給藥裝置——向全球製藥與生物科技公司銷售。
其模式為耗材加驗證:一旦塞子或藥瓶獲納入藥物申請,轉換供應商成本高昂,故銷量跟隨藥物生產。FY2025 收入為 $3,074M,同比增長 6.3%(FY2024 為 $2,893M),營業利潤為 $636M,淨利潤為 $493.7M,攤薄每股收益為 $6.83。
一家來源按不同口徑報營業利潤 $617M——此處用 $636M,差異已標示。公司年末有 25 間製造廠,2026 年都柏林擴建後為 26 間;26 間並非 FY2025 數字,不作 FY2025 數字列示。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 專有產品 | — | — | — |
| 合約製造產品 | — | — | — |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1923 | The West Company 創立 |
| 2020 | 新冠疫苗量產令零件需求大增 |
| 2025 | FY2025 收入達 $3,074M,同比增長 6.3%,年末有 25 間製造廠 |
競爭地位
財務快照 — FY2025
| 總收入 | $3,074M(同比 +6.3%) |
| 營業利潤 | $636M |
| 淨利潤 | $493.7M |
| 攤薄每股收益 | $6.83 |
主要風險
對標普500的重要性
西氏製藥服務是標普500的注射包裝標的:指數權重 0.04%、醫療保健板塊市值第 #44,是指數對給藥零件的主要敞口。
其銷量,是生物製劑生產的常設讀數——藥瓶與塞子訂單往往先於藥物銷售變動。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | 西氏製藥服務 FY2025 業績/Form 10-K,2026 年 2 月 17 日提交(財政年度截至 2025 年 12 月 31 日)、公司簡介來源 |
| 板塊分類 | GICS(生命科學工具與服務),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 13:13 · updated 2026-11-15 00:18 · rev 5